

**PB 15 of 2025**

**National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2025 (No. 2)**

*National Health Act 1953*

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

I, REBECCA RICHARDSON, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 98C(1) of the *National Health Act 1953*.

Dated 24 February 2025

**REBECCA RICHARDSON**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 2

1 Name

1. This instrument is the *National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2025 (No. 2)*.
2. This instrument may also be cited as PB 15 of 2025.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. *The whole of this instrument* | *1 March 2025* | *1 March 2025* |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

1. Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 98C(1) of the *National Health Act 1953*.

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

*National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)*

1. Schedule 1, entries for Amoxicillin with clavulanic acid

*omit:*

|  |  |
| --- | --- |
| Amoxicillin with clavulanic acid | Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 100 mL (S19A) |

1. Schedule 1, entries for Azithromycin

*omit:*

|  |  |
| --- | --- |
| Azithromycin | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL (S19A) |

1. Schedule 4, entries for Amoxicillin with clavulanic acid

*omit:*

|  |  |
| --- | --- |
| Amoxicillin with clavulanic acid | Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 100 mL (S19A) |

1. Schedule 4, entries for Azithromycin

*omit:*

|  |  |
| --- | --- |
| Azithromycin | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL (S19A) |

1. Schedule 4, entries for Budesonide with formoterol

*omit:*

|  |  |
| --- | --- |
| Budesonide with formoterol | Pressurised inhalation containing budesonide 50 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses |

1. Schedule 4, after entry for Esomeprazole and clarithromycin and amoxicillin in the form Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate)

*insert:*

|  |  |
| --- | --- |
| Estradiol | Transdermal gel (pump pack) 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses |

1. Schedule 4, after entry for Estradiol in the form Transdermal patches 1.56 mg, 8

*insert:*

|  |  |
| --- | --- |
| Estradiol | Transdermal patches 1.56 mg, 24 (Sandoz) (S19A) |

1. Schedule 4, after entry for Estradiol with norethisterone in the form Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8

*insert:*

|  |  |
| --- | --- |
| Estradiol with norethisterone | Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 (S19A) |

1. Schedule 4, after entry for Estradiol with norethisterone in the form Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8

*insert:*

|  |  |
| --- | --- |
| Estradiol with norethisterone | Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 (S19A) |

1. Schedule 4, after entry for Prednisolone with phenylephrine

*insert:*

|  |  |
| --- | --- |
| Progesterone and estradiol | Pack containing 30 capsules progesterone 100 mg (micronised) and transdermal gel (pump pack) estradiol 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses |

1. Schedule 4, entries for Timolol

*omit:*

|  |  |
| --- | --- |
| Timolol | Eye drops (gellan gum solution) 5 mg (as maleate) per mL, 2.5 mL (S19A) |